Loading...

DXCM DEXCOM INC Management Changes 8-K Filing

DXCM

DXCM

DEXCOM INC

(DXCM)

2025 8-K

Summary

Summary

Leadership Change

Equity Offerings

Board Appointment

FDA Warning Letter

Financial Results

Financial Results

Patent Settlement

Financial Results

Financial Results and Share...

Annual Meeting of Stockholders

Financial Results Announcement

Termination of Warrants

Financial Results Announcement

Preliminary Financial Results

Share Repurchase Agreement

Financial Results Announcement

Share Repurchase Program

Earnings Reports

Regulation FD Disclosure

Severance Plan Amendments

Sale of Convertible Senior ...

Earnings Reports

Financial Results Announcement

Financial Results

External Links:

Dexcom Inc. announced that CEO Kevin R. Sayer is on medical leave as of September 14, 2025. Jacob S. Leach steps in as interim CEO and Mark Foletta as interim chairman during this period.

AI Assistant

DEXCOM INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.